Page last updated: 2024-10-18

glycerol and HIV Coinfection

glycerol has been researched along with HIV Coinfection in 28 studies

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.

Research Excerpts

ExcerptRelevanceReference
"In this study of 14 days each of vaginal and rectal application of TFV reduced-glycerin 1% gel, we found only a small degree of cross-compartment distribution of TFV in RF and vaginal fluids and no pharmacodynamic activity in ex vivo testing."2.87Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. ( Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018)
" Safe and acceptable topical HIV prevention methods that target the rectum are needed."2.84MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. ( Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C, 2017)
"Glycerol and placebo were indistinguishable by colour or taste."2.76Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. ( Ajdukiewicz, KM; Cartwright, KE; French, N; Goodson, P; Lalloo, DG; Molyneux, ME; Mwambene, JB; Scarborough, M; Whitty, CJ; Zijlstra, EE, 2011)
" The latest strategies for the prevention of the sexual transmission of HIV have moved towards sustained-release dosage forms, so films may be an effective strategy that could also improve the patient's comfort."1.51Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV. ( Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Peña, J; Ruiz-Caro, R; Veiga, MD, 2019)
"00) following N-9 gel dosing and 20."1.43Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity. ( Aung, WS; Bakshi, RP; Coleman, JS; Fuchs, E; Hendrix, CW; Marzinke, MA; Robinson, J; Spiegel, HML, 2016)
"Abacavir films were prepared by solvent evaporation method using sodium alginate (Na-alginate) as the main polymer, Hydroxypropyl Methylcellulose E 15 (HPMC E 15) as the copolymer and glycerol as a humectant."1.40A novel vaginal drug delivery system: anti-HIV bioadhesive film containing abacavir. ( Bhowmik, BB; Ghosal, K; Ranjan, A, 2014)
" The OG liposome formulation with the appropriate OG/lipid ratio and dosing level had greater efficacy than either conventional gel formulation and maintained this efficacy for at least 2 months."1.38Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. ( Gupta, P; Isaacs, C; Moncla, BJ; Patton, D; Rohan, LC; Sassi, AB; Wang, L, 2012)
"Eight subjects were dosed rectally with radiolabelled and gadolinium-labelled gels to simulate microbicide gel and seminal fluid."1.38Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. ( Bakshi, RP; Caffo, BS; Cao, YJ; Du, Y; Fuchs, EJ; Grohskopf, LA; Hendrix, CW; Khan, WA; Lee, LA; Li, L; Macura, K; Wahl, RL, 2012)
" Evaluation of the panel of products showed Gynol II (a spermicidal gel containing 2% nonoxynol-9), KY Jelly, and Replens were toxic to Lactobacillus."1.38Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. ( Brown, ER; Cost, M; Dezzutti, CS; Kunjara Na Ayudhya, RP; Leblanc, MA; Moncla, B; Pickett, J; Pryke, K; Rohan, LC; Russo, J; Uranker, K; Wang, L, 2012)
"Insulin resistance has been implicated as a major factor, but the affected tissues have not been identified."1.32Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. ( Dostou, JM; Gerich, JE; Mariuz, PR; Meyer, C; Popa, EM; Reichman, RC; Welle, SL; Woerle, HJ, 2003)
"Glycerol release was higher in both HIV-infected groups, especially those without fat redistribution."1.32Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. ( Albu, JB; Engelson, ES; He, Q; Inada, Y; Ionescu, G; Johnson, JA; Kotler, DP, 2003)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.57)18.2507
2000's11 (39.29)29.6817
2010's16 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Notario-Pérez, F1
Martín-Illana, A1
Cazorla-Luna, R1
Ruiz-Caro, R1
Bedoya, LM1
Peña, J1
Veiga, MD1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L5
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L5
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Justman, JE1
Nair, GL1
Hendrix, CW4
Piper, JM2
Marzinke, MA3
Dai, JY1
Pan, Z1
Galaska, B2
Levy, L1
Schwartz, JL3
Balar, B1
Kunjara Na Ayudhya, RP3
Mushamiri, I1
McGowan, I2
Dezzutti, CS2
Ghosal, K1
Ranjan, A1
Bhowmik, BB1
Howard, LC1
Liu, CY1
Purdy, JB1
Walter, P1
Bluemke, DA1
Hadigan, C1
Coleman, JS1
Fuchs, E1
Aung, WS1
Bakshi, RP2
Spiegel, HML1
Robinson, J1
Cranston, RD1
Lama, JR1
Richardson, BA1
Carballo-Diéguez, A1
Liu, K1
Patterson, KB1
Leu, CS1
Jacobson, CE1
Parikh, UM1
Johnson, S1
Grossman, C1
Ho, KS1
Lucas, J1
Pickett, J2
Bekker, LG1
Chariyalertsak, S1
Chitwarakorn, A1
Gonzales, P1
Holtz, TH1
Liu, AY1
Mayer, KH2
Zorrilla, C1
Rooney, J1
Jones, DL1
Weiss, SM1
Chitalu, N1
Mumbi, M1
Shine, A1
Vamos, S1
Villar, O1
Poindexter, A1
Wheeless, A1
Mauck, CK2
Callahan, MM2
von Mollendorf, CE1
Van Damme, L1
Moyes, JA1
Rees, VH1
Puren, AJ1
Tweedy, K1
Taylor, D1
Magkos, F1
Mantzoros, CS1
Brouwer, MC1
van de Beek, D1
Ajdukiewicz, KM1
Cartwright, KE1
Scarborough, M1
Mwambene, JB1
Goodson, P1
Molyneux, ME1
Zijlstra, EE1
French, N1
Whitty, CJ1
Lalloo, DG1
Peltola, H1
Singhi, S1
Roine, I1
Sassi, AB1
Patton, D1
Isaacs, C1
Moncla, BJ1
Gupta, P2
Rohan, LC3
Cao, YJ1
Caffo, BS1
Fuchs, EJ1
Lee, LA1
Du, Y1
Macura, K1
Khan, WA1
Wahl, RL1
Grohskopf, LA1
Brown, ER1
Moncla, B1
Russo, J1
Cost, M1
Uranker, K1
Pryke, K1
Leblanc, MA1
Sekhar, RV1
Jahoor, F1
White, AC1
Pownall, HJ1
Visnegarwala, F1
Rodriguez-Barradas, MC1
Sharma, M1
Reeds, PJ1
Balasubramanyam, A1
Woerle, HJ1
Mariuz, PR1
Meyer, C1
Reichman, RC1
Popa, EM1
Dostou, JM1
Welle, SL1
Gerich, JE1
Kotler, DP1
Ionescu, G1
Johnson, JA1
Inada, Y1
He, Q1
Engelson, ES1
Albu, JB1
Haugaard, SB1
Andersen, O1
Pedersen, SB1
Dela, F1
Fenger, M1
Richelsen, B1
Madsbad, S1
Iversen, J1
Ratner, D1
Patterson, BK1
Kulka, K1
Parniak, MA1
Isaacs, CE1
Hillier, S1
Cade, WT1
Reeds, DN1
Mittendorfer, B1
Patterson, BW1
Powderly, WG1
Klein, S1
Yarasheski, KE1
Blümer, RM1
van Vonderen, MG1
Sutinen, J1
Hassink, E1
Ackermans, M1
van Agtmael, MA1
Yki-Jarvinen, H1
Danner, SA1
Reiss, P1
Sauerwein, HP1
Rojanapithayakorn, W1
Goedken, J1
Hammett, TM1
Mason, TH1
Joanis, CL1
Foster, SE1
Harmon, P1
Robles, RR1
Finlinson, HA1
Feudo, R1
Vining-Bethea, S1
Jeter, G1
Doherty-Iddings, P1
Seage, GR1
Heltzer, NE1
Castelvecchi, D1
Cyranoski, D1
Gibney, E1
Ledford, H1
Maxmen, A1
Morello, L1
Stoye, E1
Subbaraman, N1
Tollefson, J1
Witze, A1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women[NCT01768962]Phase 114 participants (Actual)Interventional2014-04-30Completed
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel[NCT01687218]Phase 2195 participants (Actual)Interventional2013-09-25Completed
Effects of Flourish HEC Vaginal Care System in Postpartum Women Undergoing Pelvic Physical Therapy for Birth-Related Pelvic Floor Disorders[NCT05665569]1 participants (Actual)Interventional2023-01-30Terminated (stopped due to Lack of enrollment)
Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476]98 participants (Anticipated)Interventional2022-12-31Not yet recruiting
The Effects of HIV Protease Inhibitors on Glucose Metabolism[NCT00259727]80 participants (Anticipated)Observational2006-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Pharmacokinetics: End Period Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period emtricitabine concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 1-0.35
Product 2-1.26
Product 3-1.26

Pharmacokinetics: End Period Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period tenofovir concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 10.18
Product 20.84
Product 30.02

Pharmacokinetics: End Period Tenofovir-Diphosphate (TFV-DP) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period tenofovir-diphosphate (TFV-DP) concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 11.52
Product 22.06
Product 31.54

Safety: Grade 2 or Higher Adverse Events

Compare the safety profiles of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Analysis of the primary endpoint of grade 2 or higher AEs was performed on only the evaluable participants based on the principle of intent-to-treat (ITT) whereby participants who were randomized were included in the analysis regardless of whether or not they received product in a given period (i.e, were lost to follow-up, or terminated early and/or were on a product hold). (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionparticipants (Number)
Product 164
Product 261
Product 356

Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of ease of use, a variable was created to compare regimens. This variable combines questions 1A and 1BC from Section I. Ease of Use of the MTN-017 Follow-up Behavioral Questionnaire. Categories 1 and 2 were combined and categories 3 and 4 were combined to create dichotomous variables. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Very Difficult/DifficultVery Easy/Easy
Product 114169
Product 224160
Product 318165

Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of likelihood to use product in the future, a variable was created by combining Section N. Likelihood to Use Product in the Future of the MTN-017 Follow-up Behavioral Questionnaire questions 1A, 1B, and 1C. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Very Unlikely/UnlikelyVery Likely/Likely
Product 124159
Product 252132
Product 331145

Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of liking the product, a variable was created by combining from Section H. Liking the Product of the MTN-017 Follow-up Behavioral Questionnaire question 1A and question 1BC. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Disliked Very Much/A LittleLiked Very Much/A Little
Product 116163
Product 247134
Product 338145

Adherence: Percentage of Prescribed Doses Taken Orally or Administered Rectally in an 8-week Period

Compare percentage of prescribed doses taken orally or administered rectally in an 8-week period based on the Final Converged Rates. Final Converged Rates were measured first via self-report through Short Message Service (SMS). The clinic staff also reported the most likely number of doses taken. Finally, the MTN Behavioral Research Working Group (BRWG) provided the final estimate of the number of doses taken for each participant for each period based on self-report, staff estimates and PK testing results. Note that these final judgement data are missing if PK results are missing. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
InterventionParticipants (Count of Participants)
Less Than 80%At or Greater than 80%
Product 112173
Product 231153
Product 313170

Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Sponge

Compare emtricitabine concentrations in rectal sponge among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mg (Mean)
Initiate Period FTC ConcentrationMid-Period FTC ConcentrationEnd Period FTC Concentration
Product 1-1.750.310.14
Product 2-1.76-1.76-1.80
Product 3-1.57-1.67-1.69

Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mL) in Blood Plasma

Compare emtricitabine concentrations in blood plasma among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mL (Mean)
Mid-Period FTC ConcentrationEnd Period FTC Concentration
Product 12.342.25
Product 2-0.35-0.37
Product 3-0.37-0.33

Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Sponge

Compare tenofovir concentrations in rectal sponge specimens among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mg (Mean)
Initiate Period TFV ConcentrationMid-Period TFV ConcentrationEnd Period TFV Concentration
Product 1-1.530.710.66
Product 2-1.650.971.00
Product 3-1.29-0.030.01

Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mL) in Blood Plasma

Compare tenofovir concentrations in blood plasma among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mL (Mean)
Mid-Period TFV ConcentrationEnd Period TFV Concentration
Product 11.851.77
Product 20.420.37
Product 3-0.01-0.02

Reviews

1 review available for glycerol and HIV Coinfection

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016

Trials

8 trials available for glycerol and HIV Coinfection

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
    Journal of acquired immune deficiency syndromes (1999), 2018, 06-01, Volume: 78, Issue:2

    Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Body Fluids; Dose-Response Relationship, Dr

2018
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 03-01, Volume: 64, Issue:5

    Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Female; Gels; Glycerol; HIV Infections; HI

2017
Safety evaluation of 1% tenofovir gel in healthy men.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Cellulose; Circumcision, Male; Gels; Glycerol; HI

2009
Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly.
    Contraception, 2010, Volume: 81, Issue:3

    Topics: Adolescent; Adult; Anti-Infective Agents, Local; Cellulose; Contraceptive Devices, Female; Feasibili

2010
Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:4

    Topics: Adjuvants, Pharmaceutic; Adult; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combinatio

2011
Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART.
    American journal of physiology. Endocrinology and metabolism, 2007, Volume: 292, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; Body Composition; Exercise; Fasting; Fatty Acids; Fema

2007
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    AIDS (London, England), 2008, Jan-11, Volume: 22, Issue:2

    Topics: Adiponectin; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Glucos

2008

Other Studies

20 other studies available for glycerol and HIV Coinfection

ArticleYear
Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV.
    International journal of pharmaceutics, 2019, Oct-30, Volume: 570

    Topics: Adhesives; Administration, Intravaginal; Animals; Anti-HIV Agents; Cell Line; Chemistry, Pharmaceuti

2019
A novel vaginal drug delivery system: anti-HIV bioadhesive film containing abacavir.
    Journal of materials science. Materials in medicine, 2014, Volume: 25, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Alginates; Animals; Anti-HIV Agents; Chromatography, High Pressu

2014
Lipolytic Rate Associated With Intramyocardial Lipid in an HIV Cohort Without Increased Lipolysis.
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:1

    Topics: Abdominal Fat; Adult; Aging; Body Composition; Cohort Studies; Cross-Sectional Studies; Diabetes Mel

2016
Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity.
    Contraception, 2016, Volume: 93, Issue:4

    Topics: Adolescent; Adult; Anti-Infective Agents; Cell Membrane Permeability; Cellulose; Female; Gels; Glyce

2016
Acceptability and use of sexual barrier products and lubricants among HIV-seropositive Zambian men.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:12

    Topics: Adult; Condoms; Condoms, Female; Female; Glycerol; HIV Infections; HIV Seropositivity; Humans; Lubri

2008
Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:6

    Topics: Adiponectin; Adipose Tissue; Antiretroviral Therapy, Highly Active; Dyslipidemias; Fatty Acids, None

2011
Glycerol in bacterial meningitis: one strike and out?
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:4

    Topics: Adjuvants, Pharmaceutic; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Glycerol;

2011
Glycerol in meningitis should not be condemned so hastily.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:12

    Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Female; Glycerol; HIV Infections; HIV Seroprevalence

2011
Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention.
    Drug development and industrial pharmacy, 2012, Volume: 38, Issue:8

    Topics: Administration, Intravaginal; Adult; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Chemist

2012
Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:6

    Topics: Administration, Rectal; Adult; Anti-Infective Agents; Cellulose; Colon; Gadolinium; Gadolinium DTPA;

2012
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Cellulose; Epithelial Cells; Female; Glycerol; HIV Infect

2012
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Cellulose; Epithelial Cells; Female; Glycerol; HIV Infect

2012
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Cellulose; Epithelial Cells; Female; Glycerol; HIV Infect

2012
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Cellulose; Epithelial Cells; Female; Glycerol; HIV Infect

2012
Metabolic basis of HIV-lipodystrophy syndrome.
    American journal of physiology. Endocrinology and metabolism, 2002, Volume: 283, Issue:2

    Topics: Adipocytes; Adipose Tissue; Energy Metabolism; Esterification; Fasting; Fatty Acids; Glycerol; Hepat

2002
Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.
    Diabetes, 2003, Volume: 52, Issue:4

    Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Body Constitution; C-Peptide; CD4 Lymphocyte

2003
Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Volume: 37 Suppl 2

    Topics: Adipose Tissue; Adult; Anti-HIV Agents; Blood Proteins; Body Composition; Complement C3a; Cross-Sect

2003
Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.
    Metabolism: clinical and experimental, 2006, Volume: 55, Issue:2

    Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Cross-Sectional Studies; Fatty Acids, Nonest

2006
Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:5

    Topics: Anilides; Anti-Infective Agents; Anti-Retroviral Agents; beta-Cyclodextrins; Cervix Uteri; Female; F

2006
Lubrication use in condom promotion among commercial sex workers and their clients in Ratchaburi, Thailand.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1995, Volume: 78, Issue:7

    Topics: Adolescent; Adult; Cellulose; Condoms; Female; Follow-Up Studies; Glycerol; Health Knowledge, Attitu

1995
Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities.
    Sexually transmitted diseases, 2000, Volume: 27, Issue:2

    Topics: Administration, Intravaginal; Adult; Anti-Infective Agents; Drug Combinations; Female; Follow-Up Stu

2000
Use of commercial lubricants to prevent vaginal and rectal transmission of HIV.
    The AIDS reader, 2001, Volume: 11, Issue:9

    Topics: Disease Transmission, Infectious; Female; Glycerol; HIV Infections; Humans; Lubrication; Male

2001
The science news events that shaped 2019.
    Nature, 2019, Volume: 576, Issue:7787

    Topics: Agriculture; Animals; Artificial Intelligence; Astronomy; Bullying; CRISPR-Cas Systems; Embryo Resea

2019